bluebird bio, Inc. (BLUE) entered a merger agreement on February 21, 2025, to be taken private by Carlyle (CG) and SK Capital Partners, in a deal valued at about $156.05 million.
Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird’s current product portfolio achieves $600 million in net sales in any trailing 12-month period before or ending on December 31, 2027.